ICORG 10-14: NEOadjuvant trial in Adenocarcinoma of the oEsophagus and oesophagoGastric junction International Study (Neo-AEGIS)

@inproceedings{Reynolds2017ICORG1N,
  title={ICORG 10-14: NEOadjuvant trial in Adenocarcinoma of the oEsophagus and oesophagoGastric junction International Study (Neo-AEGIS)},
  author={J P Reynolds and SR Preston and Blair O’Neill and Lene Baeksgaard and S J Griffin and Christophe Mariette and Sandra Cuffe and Micheal Cunningham and Thomas David Lewis Crosby and Ivana Parker and Kenneth Francis Hofland and Gilgamesh Hanna and LB Svendsen and C Donohoe and Conor Muldoon and Declan O’Toole and Craig Johnson and Naraymasamy Ravi and Gwilym Jones and AK Corkhill and Marianne Illsley and J Mellor and Karla Chui Luan Lee and Malek Dib and Vittorio Marchesin and Mary F Cunnane and Kathleen Scott and P Lawner and Suzette Warren and SM O’Reilly and G O’Dowd and Guillaume L{\'e}onard and Bryan T. J. Hennessy and R Mc Dermott},
  booktitle={BMC Cancer},
  year={2017}
}
Neoadjuvant therapy is increasingly the standard of care in the management of locally advanced adenocarcinoma of the oesophagus and junction (AEG). In randomised controlled trials (RCTs), the MAGIC regimen of pre- and postoperative chemotherapy, and the CROSS regimen of preoperative chemotherapy combined with radiation, were superior to surgery only in RCTs that included AEG but were not powered on this cohort. No completed RCT has directly compared neoadjuvant or perioperative chemotherapy and… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 28 references

Common data items in seven European oesophagogastric ancer srugery registeries: towards a European upper GI audit (EURECCA upper GI)

  • WO De Steur, D Henneman, WH Allim, JL Dikker
  • Eur J Surg Oncol
  • 2014
1 Excerpt

Similar Papers

Loading similar papers…